Fractyl Health Inc. Commo... (GUTS)
1.57
0.01 (0.64%)
At close: Mar 03, 2025, 3:59 PM
1.48
-5.73%
Pre-market: Mar 04, 2025, 08:00 AM EST
No 1D chart data available
| Bid | 1.4 |
| Market Cap | 75.52M |
| Revenue (ttm) | 97.25K |
| Net Income (ttm) | -63.07M |
| EPS (ttm) | -1.58 |
| PE Ratio (ttm) | -0.99 |
| Forward PE | -0.78 |
| Analyst | Buy |
| Ask | 1.48 |
| Volume | 249,389 |
| Avg. Volume (20D) | 331,439 |
| Open | 1.58 |
| Previous Close | 1.56 |
| Day's Range | 1.48 - 1.58 |
| 52-Week Range | 1.37 - 10.50 |
| Beta | -0.30 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform ...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 122
Stock Exchange NASDAQ
Ticker Symbol GUTS
Website https://fractyl.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GUTS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 536.94% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Earnings Surprise
Fractyl Health Common Stock has released their quartely earnings
on Mar 3, 2025:
4 months ago
+16.46%
Fractyl Health shares are trading higher after the...
Unlock content with
Pro Subscription
11 months ago
-9.53%
Fractyl Health shares are trading lower amid possible volatility. The company yesterday initially spiked after it announced FDA IDE approval for the Revita Remain-1 pivotal study and then rebounded after reporting Q4 financial results.
